Indegene Limited

Morgan Stanley bought 665,048 shares of Indegene Limited in a block deal on August 6, 2026, for ₹34.92 crore at ₹525.00 apiece.

A provider of analytics, technology, and specialized services to life science and healthcare organizations worldwide. Indegene delivers integrated solutions spanning commercial, medical, regulatory, and safety domains, combining data-driven insights with advanced technology platforms. The company serves pharmaceutical, biotech, and healthcare firms seeking to optimize operations, enhance decision-making, and improve market performance through evidence-based approaches and digital transformation.

US-based global investment bank. India FPI activity covers proprietary, market-making and client flows in listed Indian equities.